Innovative Decision Support InferMed's flagship Arezzo decision support technology is recognized for its role in improving clinical practice and patient safety, demonstrating a strong value proposition for healthcare providers seeking to enhance diagnostic accuracy and treatment consistency.

Global Market Reach With its solutions accessed over a million times per month across Europe, North America, and Australasia, InferMed has established a substantial international presence, presenting opportunities to expand sales into new geographic regions or deepen penetration in existing markets.

Recent Acquisition Advantage Its acquisition by Elsevier in 2015 positions InferMed within a global leader in scientific and medical information, offering avenues for cross-promotion, integration into broader healthcare data solutions, and enhanced credibility to attract new clients.

Regulatory and Innovation Edge InferMed’s recognition through the Queen’s Award for Enterprise in Innovation highlights its cutting-edge approach and industry validation, making it appealing to healthcare organizations that prioritize innovative, evidence-based decision support tools.

Growth and Revenue Potential Operating with a revenue range of up to $10 million and a focused product suite, there are significant opportunities to upsell and expand within existing client bases, as well as to target similar organizations seeking proven clinical decision solutions.